Results 41 to 50 of about 11,256 (207)

PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer

, 2022
BACKGROUND: Triple-negative breast cancer (TNBC) lacks biomarkers for targeted therapy. Auger emitters display the best therapeutic effect, if delivered directly into the nucleus proximal to DNA. The nuclear protein Poly (ADP-ribose)-Polymerase 1 (PARP1)
Terhorst, Steven, Mottaghy, Felix, Mottaghy, Felix M., Vogg, Andreas T J, Florea, Alexandru, Allekotte, Susanne, Mottaghy, Felix M, Maurer, Jochen, Bolm, Carsten, Vogg, Andreas, Morgenroth, Agnieszka, Vogg, Andreas T. J., Allekotte, Susanne Maria, Schäfer, Laura, Bauwens, Matthias, Ambur Sankaranarayana, Ramya, Classen, Arno   +16 more
core   +1 more source

Additional file 1 of PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer

, 2022
Additional file 1. Fig. S1. Reaction scheme of the radiosynthesis of [123/125I]PARPi-01. Fig S2. [18F]FDG based PET/CT therapy monitoring. Fig S3. Tumour growth curve based on CT based images for individual mice. Fig S4. TUNEL and H&E staining of tissues
Agnieszka Morgenroth (4254874), Laura Schäfer (6235379), Carsten Bolm (1409422), Ramya Ambur Sankaranarayana (13799078), Felix M. Mottaghy (13799093), Susanne Allekotte (13799084), Matthias Bauwens (319508), Arno Classen (13799090), Alexandru Florea (13799081), Andreas T. J. Vogg (13799087), Jochen Maurer (212569), Steven Terhorst (4325242)   +11 more
core   +1 more source

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

eLife, 2020
It is being increasingly appreciated that the immunomodulatory functions of PARP1 inhibitors (PARPi) underlie their clinical activities in various BRCA-mutated tumors. PARPi possess both PARP1 inhibition and PARP1 trapping activities.
Chiho Kim, Xu-Dong Wang, Yonghao Yu
doaj   +1 more source

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

BMC Medicine, 2023
Background PARP inhibitor (PARPi), as a kind of DNA damage repair inhibitor, has been shown to be effective in various solid tumors and hematologic malignancies.
Jiazhuo Wu, Cunzhen Shi, Hongwen Li, Wenting Song, Shuo Huang, Jianxiang Zhang, Wencai Li, Zhaoming Li, Mingzhi Zhang   +8 more
doaj   +1 more source

Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer

healthbook TIMES. Oncology Hematology, 2021
Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment of high-grade epithelial ovarian cancer (EOC), with demonstrated efficacy in the recurrent as well as newly diagnosed disease.
Ilaria Colombo
doaj   +1 more source

Quantification of PARPi-FL uptake after irradiation.

, 2016
Specific uptake of PARPi-FL into FaDu (A) and Cal27 (B) cells was determined by flow cytometry after incubation of cells with PARPi-FL or Olaparib/PARPi-FL. Olaparib competes with PARPi-FL for specific binding sites on PARP1.
Wolfgang A. Weber (226149), Thomas Reiner (848165), Susanne Kossatz (848164)   +2 more
core   +1 more source

SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes

Cancer Biology & Therapy
Purpose Metastatic castration-resistant prostate cancer (mCRPC) remains a significant therapeutic challenge and a leading cause of cancer-related mortality in men.
Xin Zhao, Shiyun Feng, Xiaoping Nitie, Shibu Muluo, Yi Lei   +4 more
doaj   +1 more source

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: A single institutional experience

Journal of Ovarian Research
Abstract Objective Negligible evidence exists for PARPis maintenance treatment rechallenge in patients with recurrent epithelial ovarian cancer (EOC) in China. Methods We included patients diagnosed with primary EOC who received 2 lines of PARPis maintenance treatment after achieving complete response (CR) or partial response (PR) with the ...
Yuan, Hua, Wang, Tonghui, Yao, Hongwen, Wu, Lingying, Li, Ning   +4 more
openaire   +2 more sources

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer

Scientific Reports, 2023
Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial response to chemotherapy.
Skye Alexandre Sauriol, Euridice Carmona, Molly L. Udaskin, Nikolina Radulovich, Kim Leclerc-Desaulniers, Robert Rottapel, Amit M. Oza, Stephanie Lheureux, Diane M. Provencher, Anne-Marie Mes-Masson   +9 more
doaj   +1 more source

Construction of PARPi Resistance-related Competing Endogenous RNA Network

Current Genomics, 2022
Objective: Ovarian cancer is the common gynecological malignancy in women. PARP inhibitors (PARPi) have been approved for ovarian cancer treatment. However, the primary and acquired resistance have limited the application of PARPi. The mechanisms underlying remain to be elucidated.
Kong, Lili, Xu, Jiaqi, Yu, Lijun, Liu, Shuo, Liu, Zongjian, Xiang, Juanjuan   +5 more
openaire   +2 more sources